Bitter pills: on Court’s intervention, drug pricing
The Supreme Court did well to intervene in drug pricing by retailers
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The has strongly criticized the massive disparities—sometimes up to 1000%—between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of essential drugs, particularly cancer medications. This practice, driven by a loophole in the , creates an incentive structure where pharmaceutical companies offer high MRPs and low PTRs to hospitals, effectively providing a financial reward (kickback) for stocking specific, more expensive brands. The Court’s intervention highlights a critical failure in regulatory oversight, leaving vulnerable patients facing severe financial strain due to artificially inflated medical costs.
UPSC Perspectives
Governance
The core issue highlighted is a significant regulatory failure and a loophole in the (DPCO). While the (NPPA) caps the MRP of scheduled drugs based on market averages, it does not regulate the trade margins (the difference between PTR and MRP) for hospital transactions. This allows hospitals to negotiate a low PTR from manufacturers but still bill patients or the government at the higher capped MRP, pocketing the difference. This structure creates a perverse incentive, effectively functioning as an economic kickback, where hospitals prioritize brands offering the largest profit margins rather than the most affordable options for patients. Furthermore, the has noted that tying drug purchases to in-house pharmacies eliminates patient choice and undermines natural market competition. For UPSC, this illustrates the challenges of market regulation in the healthcare sector, where information asymmetry exists between patients and providers, necessitating robust state intervention to protect consumer interests.
Economic
The pricing dynamics described demonstrate a clear market failure in the pharmaceutical sector. Unlike typical consumer markets, patients (the end consumers) do not choose their prescription drugs; the choice is made by the hospital or doctor. Therefore, pharmaceutical companies compete for the business of the hospitals, not the patients. To win this business, companies inflate the MRP while offering a low PTR, creating a lucrative spread for the hospital. This pricing strategy disadvantages more affordable, equivalent drugs because they generate less revenue for the healthcare provider. The Supreme Court has suggested a fixed percentage markup across all drugs, but the editorial argues for a regressive margin—where the percentage markup decreases as the drug price increases. This economic tool is designed to neutralize the incentive for sellers to favor disproportionately expensive products. From a macroeconomic perspective, inflated drug prices contribute significantly to Out-of-Pocket Expenditure (OOPE), which is a major driver of medical impoverishment in India.
Social
The societal impact of this pricing structure is severe, particularly concerning the constitutional mandate under (Right to Life), which the Supreme Court has interpreted to include the right to health and accessible medical care. The inflated cost of life-saving drugs, such as cancer treatments, places immense financial strain on patients and their families. High costs directly impact treatment adherence, especially for chronic conditions, as patients may ration or abandon expensive regimens they cannot afford. The practice disproportionately affects vulnerable populations who lack comprehensive health insurance, pushing them further into poverty. The intervention by the , especially following previous reluctance in similar cases (e.g., Siddharth Dalmia, 2025), underscores the judiciary's role in addressing systemic inequities when the executive and legislative branches fail to implement adequate safeguards. This highlights the ongoing challenge of achieving Universal Health Coverage and ensuring equitable access to healthcare resources in India.